Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834338 | 0.86 | HPGDS (0.51) | PDE10ACYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL2843288 | 0.83 | CYP2A6 (0.52) | PDE10ACYP19A1CYP2A6CYP2E1CYP2C9 | |
| SCHEMBL6272208 | 0.81 | PDE10A (0.49) | PDE10ACYP19A1CYP2A6CYP2E1CYP2C9 | |
| SCHEMBL2315399 | 0.79 | HPGDS (0.53) | PDE10ACYP19A1CYP2A6CYP2E1CYP2C9 | |
| SCHEMBL2833957 | 0.79 | HPGDS (0.48) | LTA4HCYP2A6CYP2C9CYP2C19CYP11B1 | |
| SCHEMBL2315346 | 0.75 | PDE10A (0.43) | PDE10ACYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL2313376 | 0.73 | NPY5R (0.67) | LTA4HHPGDSPOLBMAPTNPSR1 | |
| SCHEMBL2834854 | 0.72 | PDE3B (0.49) | PDE10AHPGDSALDH1A1 | |
| SCHEMBL2314262 | 0.72 | HPGDS (0.56) | LTA4HCYP11B1CYP11B2HPGDSPOLB | |
| SCHEMBL27656597 | 0.70 | PDE10A (0.54) | PDE10ACYP19A1CYP2A6CYP2E1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350059-B1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEM CO (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9126973-B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150099748-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-04-09 | — | — | US | disclosed |
| US-8536185-B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| US-8450326-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20130079375-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-03-28 | — | — | US | disclosed |
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | PDE10A 1415/4885CYP19A1 1694/4885LTA4H 36/4885 |
| US-20130079375-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | PDE10A 1415/4885CYP19A1 1694/4885LTA4H 36/4885 |
| US-20150099748-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | PDE10A 1415/4885CYP19A1 1694/4885LTA4H 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.